Our Latest News

This page features the latest updates from Mode Sensors. Here, we share key milestones, innovations, research findings, and collaboration projects. Stay tuned to keep up with our progress and how we are improving hydration monitoring for healthcare and beyond.

Sign up to our newsletter

Mode Sensors Announces the Start of Clinical Trial at Solfjellhøgda

Trondheim, Norway — January 25, 2025

Mode Sensors (MODE) is pleased to announce the initiation of a new clinical trial at Solfjellhøgda Rehabilitation Centre, focusing on the evaluation of its groundbreaking hydration monitoring technology, Re:Balans. The trial aims to assess the technology's effectiveness in improving hydration management for patients in rehabilitation care.

"This trial marks an exciting step forward in our mission to establish a new global standard for hydration monitoring," said Gøran van den Burgt, CEO of Mode Sensors.

Solfjellshøgda Helsehus is one of four healthcare centers in Oslo Municipality, offering 142 patient rooms dedicated to assessment and rehabilitation services. The rehabiliation centre has long experience with sensor-technology and other welfare technology.

Mode Sensors' Hydration Monitoring Technology Featured in BMC Nephrology

Trondheim, Norway — January 8, 2025

Mode Sensors (MODE) is proud to announce that its innovative hydration monitoring technology has been featured in a peer-reviewed article published in BMC Nephrology. The study, titled "Measuring fluid balance in end-stage renal disease with a wearable bioimpedance sensor," highlights the potential of MODE's flagship product, Re:Balans, to provide accurate, real-time hydration insights. You can read the full article here.

“This publication underscores Re:Balans ability to accurately track hydration changes in continously and in real-time. It reinforces our mission to set a new global standard for hydration monitoring and management,” said Gøran van den Burgt, CEO of Mode Sensors.

Lockheed Martin to Invest in Groundbreaking Hydration Monitoring Technology

Trondheim, Norway — December 10, 2024

Mode Sensors (MODE) has signed a $1.78 million contract with Lockheed Martin to test and co-develop advanced hydration sensing technology for cockpit environments. The partnership includes financial investment, knowledge transfer, and engineering collaboration from Lockheed Martin.

Enhancing Pilot Safety and Performance
Hydration plays a critical role in mission success and safety in military aviation. Even 1% dehydration can impair cognitive and physical performance, reducing g-force tolerance, increasing cardiac stress, and affecting decision-making, memory, and attention.

Integrating Hydration Data into Pilot Monitoring Systems
The collaboration aims to integrate real-time hydration data into Lockheed Martin’s pilot health monitoring systems for pre-flight preparations, in-flight safety, and post-flight recovery. This advancement will enhance pilot performance and mitigate risks associated with dehydration.

“Access to real-time hydration data will allow aviators to proactively manage hydration, avoid physiological events, and optimize performance,” said Keith Higginbotham, Associate Fellow, Aviation Physiology, Lockheed Martin Aeronautics.

“This collaboration with Lockheed Martin validates our technology and accelerates our development efforts. It positions us to explore new markets, from industrial worker safety to sports and consumer applications,” said Gøran van den Burgt, CEO of Mode Sensors.

Mode Sensors' Hydration Monitoring Technology Featured in Peer-Reviewed Journal

Trondheim, Norway — November 20, 2024

Mode Sensors (MODE) is pleased to announce that its innovative hydration monitoring technology has been featured in a peer-reviewed article published in the Journal of Clinical Monitoring and Computing. The study, titled "Continuous Non-Invasive Monitoring of Hydration Status Using Wearable Sensors," highlights the accuracy of MODE's flagship product, Re:Balans, in real-time hydration monitoring. You can read the full article here.

"This recognition by the scientific community underscores our dedication to advancing wearable sensor technology and achieving our vision of establishing a new global standard for hydration monitoring,” said Gøran van den Burgt, CEO of Mode Sensors.

Mode Sensors Achieves ISO 13485 Certification for Medical Device Quality Management

Trondheim, Norway — June 27, 2024

Mode Sensors (MODE) is proud to announce its certification under ISO 13485, the internationally recognized standard for quality management systems in the medical device industry. This certification underscores MODE’s commitment to delivering safe, reliable, and high-quality wearable healthcare solutions, including its flagship product, Re:Balans.

“Achieving ISO 13485 certification is a major milestone for Mode Sensors, validating our dedication to meeting the highest standards in medical device development,” said Gøran van den Burgt, CEO of Mode Sensors. “This certification strengthens our ability to bring innovative hydration monitoring technology to market with the utmost focus on safety and effectiveness.”

Mode Sensors Granted Patent for Breakthrough Hydration Monitoring Technology

Trondheim, Norway — June 24, 2024

Mode Sensors (MODE) is proud to announce the granting of a patent for its innovative hydration monitoring technology in Norway under patent no. 348019. This milestone reinforces MODE’s position as a leader in wearable hydration monitoring solutions, with its flagship product, Re:Balans, revolutionizing hydration monitoring to improve safety, performance, and well-being across multiple industries.

Mode Sensors Secures Collaboration Agreement with Leading U.S. Medical Device Manufacturer

Trondheim, Norway — March 28, 2024

Mode Sensors (MODE) is pleased to announce a collaboration agreement with a leading U.S. medical device manufacturer to test Re:Balans technology for a new patient indication. As part of the collaboration, MODE will provide both products and analytical services, for which the company will receive financial compensation.

"This partnership underscores the versatility and relevance of the Re:Balans technology across diverse patient populations," said Martin Engebretsen, CMO and co-founder of MODE. "The potential market impact is tremendous, and if successful, this project could prove commercially transformative for the company."